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OBJECTIVE—Insulin resistance develops in tandem with obe-
sity. Ablating myostatin (Mstn) prevents obesity, so we investi-
gated if Mstn deﬁciency could improve insulin sensitivity. A
loss-of-function mutation (Mstn
Ln) in either one or both alleles of
the Mstn gene shows how Mstn deﬁciency protects whole-body
insulin sensitivity.
RESEARCH DESIGN AND METHODS—Mstn
Ln/Ln mice were
weaned onto a high-fat diet (HFD) or standard diet. HFD-fed
Mstn
Ln/Ln mice exhibited high lean, low-fat body compositions
compared with wild types. Wild-type and heterozygous and
homozygous mutant mice were bled to determine basal levels of
insulin, glucose, and homeostasis model assessment of insulin
resistance. To evaluate postprandial insulin sensitivity between
animals of a similar size, glucose and insulin tolerance tests and
hyperinsulinemic-euglycemic clamp studies were performed
with heterozygous and homozygous mutant mice. Quantitative
RT-PCR quantiﬁed TNF, IL-6, IL-1, F4/80, GPR43, and CD36
expression in muscle, fat, and liver. Histological analysis mea-
sured hepatosteatosis.
RESULTS—Homozygous mutants were glucose tolerant and
protected against overall insulin resistance compared with het-
erozygous mice. Hyperinsulinemic-euglycemic clamp studies re-
vealed a dramatically improved glucose infusion rate, glucose
disposal rate, and hepatic glucose production in 11-month-old
Mstn
Ln/Ln mice on an HFD. Improvements to muscle and liver
insulin sensitivity (200–400%) correlated with 50–75% de-
creased tumor necrosis factor (TNF) production and coincided
with severe Mstn deﬁciency. Hepatosteatosis appeared to be
ameliorated. Short-term treatment of Mstn
Ln/Ln mice with
recombinant Mstn led to increased plasma TNF and insulin
resistance.
CONCLUSIONS—We ﬁnd that severe Mstn deﬁciency caused
by Ln (lean) mutations in HFD-fed mice protects muscle and liver
against obesity-induced insulin resistance. Diabetes 58:1133–
1143, 2009
M
yostatin (Mstn; also called Gdf-8) is a trans-
forming growth factor- family member that
is predominantly expressed in skeletal mus-
cle tissue (1,2). Mstn negatively regulates
muscle mass (2,3) and is a potent regulator of adipogene-
sis (4,5). Knockout of the Mstn gene (Mstn) from agouti
lethal yellow (A
y) and obese (Lep
ob/ob) mice improves
glucose tolerance, increases muscle mass, and decreases
adiposity (6). Obesity-prone A
y and Lep
ob/ob Mstn null mice
have body sizes roughly equal to those of their littermate
controls due to a diametrical change in muscle and fat
characterized by fewer adipocytes that are reduced in size
and hyperplasia and hypertrophy of individual muscle
ﬁbers. In addition, Mstn knockout mice exhibit an ability
to fend off age-related expansion of adipose tissue mass by
keeping their fat cells small, unlike wild types, which have
enlarged adipocytes contributing to increasing adiposity
with age. Evidently, knockout mice experience continued
protection against obesity over the later part of their
lifespan as they age compared with wild-type mice, yet
they have similar total and resting metabolic rates.
Here, we describe a novel, loss-of-function allele of
Mstn (Mstn
Ln) identiﬁed from a forward genetic screen
of N-ethyl-N-nitrosourea (ENU)-mutagenized mice chal-
lenged with a high-fat diet (HFD). HFD-fed mice with the
Ln (lean) mutations displayed altered body compositions
consistent with the in vivo effects on growth produced by
Mstn deﬁciency. The loss-of-function Mstn mutation pre-
vented obesity, decreased plasma insulin, and normalized
the body weights of heterozygous and homozygous mice.
Therefore, we studied relationships among partial Mstn
deﬁciency, lipid utilization, and whole-body insulin sensi-
tivity by comparing animals of a similar size to avoid the
complicating factor of differences in body weight. Hyper-
insuliemic-euglycemic clamp studies performed in aged
HFD-fed Mstn
Ln/Ln and Mstn
/Ln mice showed that there
was a marked improvement to muscle and liver insulin
sensitivity, and this was associated with reduced steatosis
and decreased tumor necrosis factor (TNF) and interleu-
kin (IL)-6 gene expression in muscle and fat but not in
liver.
RESEARCH DESIGN AND METHODS
Generation, housing, and diet. ENU-mutagenized C57BL/6 (B6) mice were
generated as described (7). Mice were maintained by backcrossing affected
animals to B6. Animals were housed in the Genomics Institute of the Novartis
Research Foundation speciﬁc pathogen–free animal facility. All procedures
were approved by the institutional animal care and use committee at the
Genomics Institute of the Novartis Research Foundation. Mice were provided
with an HFD at weaning, deriving 58% of its calories from fat (D12331;
Research Diets, New Brunswick, NJ). After 8 consecutive weeks on an HFD,
mice were identiﬁed as affected or not after an evaluation of plasma hormones
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DIABETES, VOL. 58, MAY 2009 1133and whole-body composition. A loss-of-function Mstn mutation was found to
be present in mice bred from randomly ENU-mutagenized B6 animals within
a family we call Ln.
Mapping and genotyping. Affected B6 mice were bred to A/J mice to
generate hybrid F1 and F2 mice for mapping. Single nucleotide polymorphism
(SNP) assays across the entire genome (n  356) were performed using the
Sequenom MassARRAY system, as previously described (8). All three exons
and intron/exon junctions of Mstn were ampliﬁed by PCR and sequenced for
mutation detection. Mice were genotyped by amplifying a 93-bp segment
about the point of mutation with primers 5-GAATGGCCATGATCTTGCTG-3
and 5-GTAACACGGTTGCTAGAATG-3. An extension primer, 5-aggagaagat-
gggctgg-3, was annealed to the PCR product and extended in the presence of
dTTP (deoxythymidinetriphosphate) and dCTP (deoxycytidinetriphosphate)
to yield a 1-base extension of the primer when annealed to wild-type (dT) or
mutant (dC) template. The different extension products were distinguished by
mass spectrometry (Sequenom). One in four offspring from the F2 and
subsequent heterozygote-by-heterozygote matings were conﬁrmed to be af-
fected and homozygous mutant.
Body composition assay. Body fat and lean masses were determined in
conscious mice by nuclear magnetic resonance at 4 months of age using the
EchoMRI-100 from Echo Medical Systems (Houston, TX).
Plasma glucose, hormones, lipids, and cytokines. Glucose was measured
by a OneTouch Ultra glucometer (Lifescan, Milpitas, CA). Insulin and leptin
were measured by enzyme-linked immunosorbent assays (ELISAs) with kits
from CrystalChem (Chicago, IL). Total cholesterol, triglyceride, and free fatty
acid (FFA) measurements were performed with an AU400e auto analyzer from
Olympus America (Center Valley, PA). TNF was measured using a TiterZyme
Enzyme Immunometric Assay Kit obtained from Assay Designs (Ann Arbor,
MI). Adiponectin and IL-6 were measured by speciﬁc ELISA using kits from
Chemicon International (Temecula, CA) and R&D Systems (Minneapolis,
MN), respectively.
Glucose tolerance test. Glucose tolerance to was determined in 6-h–fasted
mice. Glucose was administered to conscious mice by intraperitoneal injec-
tion (2 g/kg). Blood was pushed from nicked tails. Blood glucose was
measured instantly using a OneTouch Ultra glucometer. Blood samples (20 l)
were collected at 0, 5, 15, and 30 min and spun (8,000 rpm/4°C). Extracted
plasma was stored at 	20°C. One week later, plasma samples were thawed
once and insulin was measured in duplicate by ELISA (CrystalChem).
Insulin tolerance test. Hand-held mice received insulin (Novolin R; Novo
Nordisk, Copenhagen, Denmark) by intraperitoneal injection (0.5 units/kg).
Glucose measurements were made at 0, 20, 40, 60, and 80 min as described for
the glucose tolerance test.
Hyperinsulinemic-euglycemic clamp studies. Animals were surgically im-
planted with dual jugular vein catheters constructed of micro-renathane (MRE
033; Braintree, MA). Afterward, mice were allowed to recover on a warm pad.
Upon awaking, mice were provided with food and water for 4 days. Fully
recovered catheterized mice were transferred to clean cages without food to
fast for 6 h. Mice were placed in a restraining device. A priming radioactive
dose (2.5 Ci) of D-[1-
3H]glucose (American Radiolabeled Chemicals, St.
Louis, MO) was given to secured mice. Thereafter, saline plus tritiated glucose
(10 Ci/ml) infusions were started at t 	 60 min. Once basal saline plus
tritium infusions had been completed, one tail vein blood sample was drawn
to obtain speciﬁc
3H activity. Two-hour hyperinsulinemic-euglycemic clamp
studies were initiated by constant tracer infusion at a rate of 0.0167 Ci/min
plus insulin (8 mU  kg
	1  min
	1) that was started at t  0 simultaneously with
a variable glucose (50% wt/vol) infusion. Glucose infusion rates (GINFs) were
adjusted by taking readings with droplets of blood and making necessary
pump rate corrections until a steady-state blood glucose level of 150 mg/dl
was reached. Final blood samples (25 l) were drawn immediately upon
completion of clamps and spun (8,000 rpm/4°C). Plasma samples (10 l) were
treated with 0.3 N zinc sulfate neutralized with barium hydroxide to remove
unwanted protein. Deproteinated samples were dried for 12 h at 42°C. Fully
dehydrated
3H samples were dissolved into high-efﬁciency liquid scintillation
counting ﬂuid and counted on an LS 6500 multipurpose scintillation counter
(Beckman, Fullerton, CA).
RNA preparation and messenger RNA quantiﬁcation. Total RNA was
prepared from 30 mg of liver or muscle and from 100 mg of white adipose
tissue using an RNeasy Mini Kit (Qiagen, Valencia, CA). RNA expression for
TNF, IL-6, IL-1, F4/80, Gpr43, and m36B4 was determined by quantitative
real-time PCR (qPCR) in a 384-well format on the Applied Biosystems 7900HT
Sequence Detection System. The following primers and probes were used:
m36B4 (forward primer, 5-AGATGCAGCAGATCCGCAT-3; reverse primer,
5-GTTCTTGCCCATCAGCACC-3; and probe, 5-CGCTCCGAGGGAAGGCCG),
TNF (forward primer, 5-GGCTGCCCCGACTACGT-3; reverse primer, 5-
GACTTTCTCCTGGTATGAGATAGCAA-3; and probe, 5-CCTCACCCACACC
GTCAGCCG), IL-1 (forward primer, 5-AATCTATACCTGTCCTGTGTAATGA
AAGAC-3; reverse primer, 5-TGGGTATTGCTTGGGATCCA-3; and probe,
5-ACACCCACCCTGCAGCTGGAGAGT), F4/80 (forward primer, 5-TTACGA
TGGAATTCTCCTTGTATATCA-3; reverse primer, 5-CACAGCAGGAAGGTG
GCTATG-3; and probe, 5-CCATGTGGGTACAGTCATCTCCCTGGTATGT),
IL-6 (forward primer, 5-TCAATTCCAGAAACCGCTATGA-3; reverse primer,
5-CACCAGCATCAGTCCCAAGA-3; and probe, 5-CTCTCTGCAAGAGACTTC
CATCCAGT), and Gpr43 (forward primer, 5-GGGATCTGGGTCACATGCTTA
T-3; reverse primer, 5-ATGTCAGACAGACGGGTACCAA-3; and probe, 5-C
TCTGTGTCACCAGTCACTGGGTCTAGGAGAT). Taqman reactions took
place in 9 l of cocktail: 150 nmol/l m36B4 primer/probe, 150 nmol/l
gene-speciﬁc primers, and 250 nmol/l gene probe plus 3 l of RNA (10 ng/l),
using an Invitrogen SuperScript III qPCR kit in accordance with the manufac-
turer’s instructions. Speciﬁc mRNA concentration was estimated from a linear
standard curve generated with 100 ng/l of freshly isolated wild-type RNA that
had been serially diluted threefold. Quantities of speciﬁc mRNAs were
normalized to m36B4 for each gene.
Detection of serine phosphorylated IRS-1/Akt by Western blotting.
Samples were prepared as described (9). Electrophoresis was performed
using precast 4–12% BIS-TRIS NuPAGE gels (Invitrogen, Carlsbad, CA).
Phospho-blots were generated with an anti-phospho insulin receptor substrate
(IRS)-1 (serine 307) antibody (Upstate Biotechnology, Lake Placid, NY) for
IRS-1 or an anti-phospho Akt (serine 473) antibody (Cell Signaling, Beverly,
MA) for Akt. Primary antibodies were used at 1:1,000 dilution. Western blots
were detected with a horseradish peroxidase–linked anti-rabbit secondary
antibody (Santa Cruz, CA) diluted 1:10,000.
Liver histological analysis. Parafﬁn-embedded or frozen livers were sliced
into 5-m sections and stained with hematoxylin and eosin or Oil Red O,
respectively, and hepatosteatosis was determined as described (9).
Treatment with recombinant Mstn. Mice received 0.4 g/day of recombi-
nant Mstn (R&D Systems, Minneapolis, MN) or placebo. Placebo was 100 lo f
PBS. Recombinant GDF-8 was diluted in 100 l of PBS and administered by
subcutaneous injections. Injections were given twice daily at 8:00 A.M. and 3:00
P.M. each day for 5 days.
Calculations and statistical analysis. Physical activity was calculated by
counting beam breaks in X and Y directions. Glucose disposal rate (GDR) and
hepatic glucose production (HGP) were calculated using Steele’s equation
(10). Oxygen utilization (VO2) was determined from the equation VO2  ViO2i 	
VOO2O, and respiratory exchange ratio was calculated as VCO2/ VO2. Heat (CV 

VO2) was calculated from an estimation of the ingested caloric value (CV)o f
food based on respiratory efﬁciency ratio (RER). Calculations for oxygen
consumption, heat production, and substrate utilization were all performed
automatically by OxyMaxWin software version 4.11. Total peak areas under
the glucose curve (AUCg) and insulin curve (AUCi) were calculated by taking
the sum of three to ﬁve individually ﬁtted triangles that had been inserted
under curves from baseline. Homeostasis model assessment of insulin resis-
tance (HOMA-IR) was calculated by multiplying AUCg and AUCi. All data were
statistically analyzed by ANOVA and t tests, as appropriate. Statistical
differences were considered signiﬁcant at P value  0.05.
RESULTS
Mstn gene mutation caused leanness. In a forward
genetic screen using ENU as the mutagen we identiﬁed a
family of mice that remained lean with low insulin despite
high-fat feeding (Fig. 1A and B). A genome-wide scan using
SNP markers in four affected and two unaffected mice
identiﬁed a 30-Mb interval on chromosome 1 inherited
with the low-fat phenotype and containing the Mstn gene.
Sequencing the Mstn gene revealed a T3C transition in
the second intron two base pairs downstream of exon 2, a
position conserved in almost all vertebrate introns (11),
which we refer to as the lean (Ln) allele of Mstn (Mstn
Ln).
Homozygous mutant males had lower basal insulin and
homozygous mutant females had lower basal glucose
and insulin than their heterozygous mutant or wild-type
littermates (Fig. 1A). Both male and female 4-month-old
Mstn
Ln/Ln mice that had been weaned onto an HFD had
signiﬁcantly higher lean mass and lower fat mass than
their Mstn
/Ln or Mstnt
Ln/Ln littermates (Fig. 1B). Mstn
/Ln
males had a lean mass intermediate to Mstn
Ln/Ln and
Mstn
/Ln. Female HFD-fed mice that were homozygous for
the ENU-induced mutation in Mstn had increased lean
mass and decreased fat compared with heterozygotes.
Heterozygous and wild-type female mice displayed similar
MYOSTATIN AND INSULIN RESISTANCE
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Mstn
Ln/Ln males had a greater amount of lean mass and
substantially less fat than females (Table 1). HFD-fed
mutants had 40% more total body fat mass compared
with those on the standard diet. Both male and female
HFD-fed Mstn mutant mice were signiﬁcantly (P  0.05)
increased in their total lean mass by 10 or 20% compared
with mice maintained on the standard diet.
The presence of an ENU-induced mutation at a highly
conserved position of a splice donor suggests that the
mutation may be exerting its effects through abnormal
splicing. We therefore examined the Mstn mRNA by
reverse transcription and PCR ampliﬁcation of the region
surrounding the junction of exons 2 and 3. RT-PCR of
mRNA from wild-type muscle yielded the expected prod-
uct of 204 bp (Fig. 2A). The mRNA from mutant animals,
however, gave rise to an additional, larger RT-PCR prod-
uct. In heterozygotes, both products are present, though
the smaller, wild-type product predominates. Sequencing
of the larger RT-PCR product from mutant muscle re-
vealed a 128-bp insert at what would normally be the
junction between exons 2 and 3 (Fig. 2B). This insertion
encodes an additional four amino acids before a prema-
ture stop codon (ASDNX). This mutant mRNA is predicted
to encode a truncated protein containing the Mstn signal
sequence and propeptide but lacking the ligand portion
of the molecule. In addition to this abnormal splicing
product, the mRNA is also reduced in abundance by
60% (Fig. 2C).
Reduced serum lipids in 6-h–fasted HFD-fed Mst-
n
Ln/Ln mice. Plasma cholesterol and triglyceride levels in
male HFD-fed Mstn
Ln/Ln mice were decreased from 15 to
20% (P  0.05) compared with HFD-fed heterozygous and
wild-type controls (Table 2). We detected no decreases in
serum cholesterol or triglyceride levels for female HFD-
fed Mstn
Ln/Ln mice compared with female heterozygous or
wild-type mice. An HFD raised plasma FFA levels in fasted
male and female Mstn
/, Mstn
/Ln, and Mstn
Ln/Ln mice
(Table 2). There were no detectable differences in basal
plasma FFA among 6-h–fasted HFD-fed Mstn
/ and
Mstn
/Ln and Mstn
Ln/Ln mice. Insulin levels were de-
creased by 3.5- and 2.5-fold (P  0.05) in male and female
HFD-fed Mstn
Ln/Ln mice, respectively, compared with
Mstn
/ and Mstn
/Ln mice.
Reduced adipokines and TNF in Mstn
Ln/Ln mice.
Compared with HFD-fed controls (Mstn
/ and Mstn
/Ln),
leptin levels were decreased by 3.4- and 9.7-fold (P  0.05)
in female and male HFD-fed Mstn
Ln/Ln mice, respectively
(Fig. 3A). Adiponectin levels in standard diet–fed Mstn
Ln/Ln
mice were signiﬁcantly (P  0.05) decreased by two- to
FIG. 1. Basal plasma glucose and insulin (A) and body composition (means  SE) (B)i nMstn
Ln family mice weaned onto an HFD. Signiﬁcantly
different from wild-type (*) or heterozygous (†) littermates, P < 0.05. A and B: ‚, Mstn
Ln/Ln; u, Mstn
/Ln; , Mstn
/. C and D: f, Mstn
/; u,
Mstn
/Ln; , Mstn
Ln/Ln.
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/ or Mstn
/Ln mice (Fig.
3B). HFD-fed Mstn
Ln/Ln males were decreased in plasma
adiponectin, while there was a nonsigniﬁcant tendency
for female HFD-fed Mstn
Ln/Ln mice to exhibit an in-
crease in adiponectin compared with HFD-fed Mstn
/Ln
mice. Plasma TNF levels were decreased 40% in male
HFD-fed Mstn
Ln/Ln mice compared with HFD-fed
Mstn
/Ln mice. Males exhibited greater plasma TNF
levels than females. We detected no sex differences for
plasma IL-6 levels.
Improved whole-body insulin sensitivity in male and
female HFD-fed Mstn
Ln/Ln mice. We saw an increase in
basal insulin of standard diet–fed Mstn
Ln/Ln females com-
pared with Mstn
/ controls, but this did not reach
statistical signiﬁcance (Table 2). However, basal insulin
levels were statistically similar between Mstn
/ and
Mstn
/Ln for HFD-fed mice of both sexes. Furthermore,
HFD-fed Mstn
/Ln animals had similar body weights to
HFD-fed Mstn
Ln/Ln animals (Fig. 1). We therefore com-
pared Mstn
/Ln and Mstn
Ln/Ln mice in our HOMA, glucose
and insulin tolerance tests, and hyperinsulinemic-euglyce-
mic clamp studies in order to avoid complications due to
different body weights of the animals being compared.
Basal insulin resistance predicted by HOMA (insulin 

glucose) was improved for both HFD-fed male Mstn
Ln/Ln
mice (P  0.05) (Mstn
/Ln  725.4  29.2; Mstn
Ln/Ln 
134.9  5.0) and HFD-fed female Mstn
Ln/Ln mice (P  0.05)
(Mstn
/Ln  207.9  3.6; Mstn
Ln/Ln  86.6  3.0). In
response to a direct insulin challenge, HFD-fed Mstn
/Ln
males showed elevated (P  0.05) blood glucose levels at
20, 40, and 60 min compared with Mstn
Ln/Ln mice (Fig. 4A).
In HFD-fed Mstn
/Ln females, glucose was signiﬁcantly
elevated at 60 (P  0.05) and 80 (P  0.05) min compared
with Mstn
Ln/Ln females (Fig. 4A). Both male and female
HFD-fed Mstn
Ln/Ln mice showed similar insulin response
curves compared with sex-appropriate, standard diet–fed
Mstn
Ln/Ln mice (Fig. 4A). Further, both sexes of HFD-fed
Mstn
Ln/Ln mice proved to be glucose tolerant (Fig. 4B) and
were markedly reduced in plasma insulin after glucose
loading compared with sex-matched HFD-fed Mstn
/Ln
controls (Fig. 4C). Postprandial insulin resistance, when
examined after adjustment for lean mass, proved to be
consistent, with male HFD-fed Mstn
/Ln 
 female HFD-fed
Mstn
/Ln 
 male HFD-fed Mstn
Ln/Ln  female HFD-fed
Mstn
Ln/Ln mice (Fig. 4D).
Protected whole-body, muscle, and liver insulin sen-
sitivity after a prolonged HFD in Mstn
Ln/Ln mice. An
HFD will continue to promote obesity and worsen insulin
resistance over prolonged periods of time. To evaluate
tissue insulin sensitivity after a prolonged HFD, we per-
formed standardized hyperinsulinemic-euglycemic clamp
studies in Mstn
/Ln and Mstn
Ln/Ln mutant mice that had
been maintained on an HFD until 10–11 months of age. At
that time, body weights of mice differed between Mstn
/Ln
and Mstn
Ln/Ln mice as a result of further separating lean
and fat masses by an HFD. Homozygous mutants (42.0 
1.3 g) were lower in weight (P  0.05) than heterozygotes
(51.5  2.0 g). HFD-fed mutants had epididymal fat pads
(0.87  0.17 g) that weighed three- to fourfold less (P 
0.05) than HFD-fed heterozygotes (2.85  0.18 g). Quadri-
ceps from HFD-fed Mstn
Ln/Ln mice (0.386  0.02 g)
weighed 1.4-fold more (P  0.05) than those from Mstn
/Ln
mice (0.289  0.01 g). Gastrocnemius muscles from HFD-
fed Mstn
Ln/Ln mice (0.378  0.03 g) weighed 1.4-fold more
(P  0.05) than those from Mstn
/Ln mice (0.278  0.02 g).
Whole-body changes in fat and lean mass were conﬁrmed
by nuclear magnetic resonance (data not shown). Whole-
body insulin sensitivity was sustained in HFD-fed Mstn
Ln/Ln
mice, as demonstrated by markedly increased (P  0.01)
GINF for older HFD-fed Mstn
Ln/Ln mice compared with
age-matched Mstn
/Ln mice (Fig. 5A). GDR and HGP were
calculated to ascertain effects on glucose homeostasis at
the level of skeletal muscle and liver. Basal levels of GDR
and HGP were similar between HFD-fed Mstn
Ln/Ln and
Mstn
/Ln mice. Insulin-stimulated levels were improved
from 200 to 400% in HFD-fed Mstn
Ln/Ln mice compared
with HFD-fed Mstn
/Ln mice (Fig. 5B and C). Measure-
ments with tissue extracts made by Western blotting
TABLE 1
Body composition of 4-month-old mice after being weaned onto HFD or standard diet
n
Weight (g)
Fat Lean Body
Male
Mstn
/ genotype
HFD 10 8.2  1.39*† 21.9  0.69* 32.3  1.37*†
Standard diet 7 3.2  0.53 21.7  1.21 28.3  1.45
Mstn
/Ln genotype
HFD 34 6.4  0.43*‡ 26.5  0.43*‡ 36.3  0.46*‡
Standard diet 5 3.1  0.33 23.8  0.47 30.3  0.68
Mstn
Ln/Ln genotype
HFD 28 0.70  0.11* 33.6  0.53*‡ 36.9  0.54*‡
Standard diet 8 0.45  0.08 27.2  0.68 29.5  0.68
Female
Mstn
/ genotype
HFD 6 5.0  0.47† 18.2  0.28 25.7  0.61†
Standard diet 8 2.0  0.07 17.7  0.32 22.1  0.42
Mstn
/Ln genotype
HFD 15 4.9  0.33† 18.8  0.28 26.2  0.51†
Standard diet 9 2.3  0.14 19.1  0.36 23.6  0.47
Mstn
Ln/Ln genotype
HFD 8 1.99  0.14† 24.3  0.44† 28.2  0.41‡
Standard diet 6 1.21  0.06 22.1  0.41 24.9  0.46
Data are means  SE. *P  0.05 vs. HFD female mice; †P  0.05; ‡P  0.01 vs. mice of the same sex and genotype on standard diet.
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Mstn
Ln/Ln mice by 400%. Serine-phosphorylated IRS-1
levels were decreased in liver of HFD-fed Mstn
Ln/Ln mice
(Fig. 5D), while insulin-stimulated Akt phosphorylation
increased in HFD-fed Mstn
Ln/Ln compared with HFD-fed
Mstn
/Ln mice (Fig. 5E).
Reduced inﬂammation in older, lean HFD-fed Mstn
Ln/Ln
mice. Tissue levels of select cytokines known to be
upregulated by the endotoxemic effects of an HFD (12)
and found to be increased directly in cultured macro-
phages upon stimulation with lipopolysaccharide (J.J.W.
and A. Gerken, unpublished observations) were quantiﬁed.
Quantitative PCR analysis revealed Tnf, Il6, Il1b, F4/80,
and Gpr43 gene expression to be reduced (P  0.05) from
50 to 75% in abdominal fat of lean male HFD-fed Mstn
Ln/Ln
mice compared with obese HFD-fed Mstn
/Ln males (Fig.
6A). Also, Tnf, Il6, F4/80, and Gpr43, but not Il1b, were
reduced (P  0.05) from 50 to 75% in skeletal muscles of
lean male HFD-fed Mstn
Ln/Ln mice compared with obese
HFD-fed Mstn
/Ln males (Fig. 6B). Figure 7 shows that the
relative gene expression levels of proinﬂammatory cyto-
kines between Mstn
/Ln and Mstn
Ln/Ln mice were similar
in liver. CD36, an abundantly expressed fatty acid trans-
porter, was decreased in liver from 70 to 90% in HFD-
fed, lean Mstn
Ln/Ln mice compared with Mstn
/Ln
controls.
Reduced hepatic lipid accumulation in HFD-fed
Mstn
Ln/Ln mice. Dysregulation of HGP could have arisen in
Mstn
/Ln mice from abnormal lipid accumulation in hepa-
tocytes. To identify liver pathology, we examined samples
FIG. 2. Molecular characterization of the Mstn
Ln allele. A: RT-PCR of Mstn mRNA from skeletal muscle of wild-type and heterozygous and
homozygous mutant animals. Top: Schematic representation of the Mstn gene. Exons are depicted as boxes and introns (not to scale) as lines.
Arrows indicate positions of primers. Bottom: Agarose gel of the RT-PCR products of mRNA from C2C12 myoblasts (MB), C2C12 myotubes (MT),
Mstn
/ muscle (WT), Mstn
/Ln muscle (Het), and Mstn
Ln/Ln muscle (Mut). B: Sequence of the Mstn mRNA from muscle of wild-type and Mstn
Ln/Ln
animals and the proteins predicted to be encoded by the respective mRNAs. C: Mstn mRNA abundance, as measured by quantitative PCR, in
samples of wild-type and mutant muscle.
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of up to 11 months. Visual inspections of liver sections
permitted by staining with hematoxylin and eosin or Oil
Red O showed that there were numerous large vacuoles
and lipid droplets present in the tissues of prolonged
HFD-fed Mstn
/Ln mice. Livers of 10- to 11-month-old
Mstn
Ln/Ln mice showed no evidence of hepatosteatosis
after an HFD (Fig. 7B).
Insulin resistance upon short-term Mstn treatment.
To determine whether Mstn could induce insulin resis-
tance, we studied females of similar body size that were
treated with Mstn or placebo. Mstn-treated mice became
insulin resistant relative to placebo-treated females (Fig.
8A) and had increased plasma TNF levels (Fig. 8B).
Treatment did not measurably affect body weights (Fig.
8C) or body composition. Unlike obesity, short-term Mstn
treatment did not increase liver weights of mice (Fig. 8D).
DISCUSSION
Our studies in ENU-mutagenized animals demonstrate that
a near-complete loss of Mstn signaling will protect male
and female mice against obesity-induced insulin resis-
tance. An antiobesity effect was not explained by heat
TABLE 2
Plasma lipids and insulin in 4-month-old male and female Mstn
/, Mstn
/Ln, and Mstn
Ln/Ln mice weaned on HFD or standard diet
Total cholesterol
(mg/dl)
HDL cholesterol
(mg/dl)
Triglycerides
(mg/dl)
FFAs
(mmol/l)
Insulin
(ng/ml)
Males
Mstn
/ HFD 291.5  27.6 124.6  13.0 118.5  12.8 1.44  0.19 2.82  0.32
Mstn
/	 HFD 231.0  15.0 99.5  4.0* 107.5  5.2* 1.42  0.04* 2.99  0.21*
Mstn
	/	 HFD 184.0  13.9†‡§ 86.9  2.6†‡§ 84.5  3.0†‡ 1.40  0.07 0.83  0.08†‡
Mstn
/ standard diet 85.0  6.2 44.0  2.7 83.0  6.0 0.88  0.05 0.87  0.44
Mstn
/	 standard diet 100.7  3.2 47.0  1.7 84.4  3.6 0.84  0.05 1.05  0.38
Mstn
	/	 standard diet 72.4  4.7 49.3  1.8 78.0  4.4 1.23  0.09 0.59  0.07
Females
Mstn
/ HFD 237.8  30.8 88.2  10.3 99.0  15.5 1.42  0.12 1.43  0.22
Mstn
/	 HFD 207.0  13.2 76.1  2.4 81.3  4.9 1.28  0.03 1.61  0.20
Mstn
	/	 HFD 173.6  17.1§ 79.9  2.8§ 83.1  4.9 1.41  0.04 0.62  0.05†‡
Mstn
/ standard diet 70.8  4.5 29.3  1.4 65.1  2.0 0.72  0.03 0.23  0.06
Mstn
/	 standard diet 69.8  2.8 31.2  0.9 69.1  2.3 0.81  0.04 0.19  0.12
Mstn
	/	 standard diet 71.5  7.3 39.4  2.3 69.3  3.4 1.16  0.08 0.56  0.02
Data are means  SE. *P  0.05 vs. HFD Mstn
/Ln females; †P  0.05 vs. HFD Mstn
/;‡ P  0.05 vs. HFD Mstn
/Ln;§ P  0.05 vs. standard
diet Mstn
Ln/Ln mice.
FIG. 3. Adipokines were decreased in homozygous Mstn mutant animals. A: Leptin. B: Adiponectin. C: Proinﬂammatory cytokines. Data are shown
as means  SE for males (n  8–9 per genotypye) and females (n  8–12 per genotype). *Signiﬁcantly different from controls (Mstn
/ and
Mstn
/Ln) of the same sex (P < 0.05). †Signiﬁcantly different from standard diet–fed mice of the same sex and genotype (P < 0.05). ‡Signiﬁcantly
different from females of the same genotype. u, Mstn
/; f, Mstn
/Ln; , Mstn
Ln/Ln.
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physical activity in Mstn knockouts (6), and these
parameters were all similar between HFD-fed Mstn
Ln/Ln
and Mstn
/Ln mice during 12-h light/dark cycles (online
appendix Table [available at http://diabetes.diabetes
journals.org/cgi/content/full/db08-0245/DC1]). The re-
sults of our studies in HFD-fed Mstn
/Ln and Mstn
Ln/Ln
mice show that beneﬁts afforded to muscle and liver
persist well beyond their initial development, as demon-
strated by 400% improvements in insulin-stimulated GDR
and HGP in 11-month-old animals. Long-term protection
of HFD-fed Mstn
Ln/Ln mice against obesity-induced insulin
resistance is associated with markedly lower levels of total
and abdominal body fatness. Our insulin sensitivity mea-
surements in Mstn
Ln/ and Mstn
Ln/Ln mice by hyperinsu-
linemic-euglycemic clamp studies revealed that both
muscle and liver insulin resistance is improved in HFD-fed
Mstn
Ln/Ln compared with Mstn
/Ln mice. Also, hepatic
steatosis consequential of being weaned and sustained on
an HFD is prevented over the long term in Mstn
Ln/Ln mice.
Proinﬂammatory cytokine production is also decreased, as
demonstrated by a 50–75% decrease in Tnf expression in
adipose and muscle but not liver. Additionally, there is a
30–50% reduction in circulating TNF levels in male
animals, which are highly affected by the Mstn mutation,
with greater quantities of muscle and fat compared with
females. Furthermore, chronic treatment of HFD-fed fe-
male Mstn
Ln/Ln mice with recombinant Mstn increases
circulating TNF levels and insulin resistance without
eliciting a change in body or liver weights.
The Ln mutation disrupts the normal splice donor site in
Mstn downstream of exon 2, and the mutant allele gives
rise to both a normally spliced transcript and an abnor-
mally spliced transcript, which includes another 128 bp
downstream of exon 2 (Mstn
Ln) mRNA. In wild-type mice,
multiple processing steps generate active Mstn ligand,
which binds activin type 2 receptors (ActRIIa and ActRIIb)
(13), from its precursor (14). Mstn
Ln mRNA encodes a
truncated protein that contains signal sequence and
propeptide but lacks the ligand portion of the molecule.
Thus, the point mutation leads to production of an incom-
plete peptide that may inhibit the mature Mstn ligand.
Furthermore, mutant Mstn mRNA is decreased, presum-
ably by nonsense-mediated decay. Heterozygotes produce
both wild-type and mutant inhibitory protein, so Mstn
signaling is expected to be reduced as a consequence of
the mutation by 
50% compared with wild type, while
homozygotes are expected to have no Mstn signaling. The
concept of systemically regulated latent Mstn peptides by
circulating polypeptide antagonists has recently been dis-
FIG. 4. Insulin resistance was normalized in HFD-fed homozygous Mstn mutant animals to levels of standard diet–fed mice. A: Insulin tolerance
test.Band C: Glucose tolerance test. , HFD Mstn
/Ln; , HFD Mstn
Ln/Ln; Œ, standard diet Mstn
Ln/Ln. HFD blood glucose was monitored during
the glucose tolerance test (B) or insulin measured thereafter (C). Data are shown as means  SE for males (n  8) and females (n  6). D: The
HOMA-IR was calculated from the glucose tolerance data as described in RESEARCH DESIGN AND METHODS. Insulin resistance was adjusted for lean
mass compared with male heterozygous mice. Level of insulin resistance was different at P < 0.01 compared with same sex Mstn
/Ln (*) or males
Mstn
/Ln (**). Bars represent the means  SE of insulin resistance calculated from AUCs.
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signaling predicted for heterozygotes can lead to increased
lean mass and reduced fat without decreased hyperinsu-
linemia. In contrast, complete Mstn deﬁciency leads to a
normalized plasma insulin levels, indicating that improve-
ments to obesity-induced insulin resistance displayed by
HFD-fed Mstn-deﬁcient mice come from either growth
independent or synergistic effects. Thus, the well-docu-
mented effect of Mstn on lean and fat mass development
linked to obesity appears to be dissociated in HFD-fed
heterozygous and homozygous mice at some level from
effects on whole-body insulin resistance. To further exem-
plify this, females homozygous for Mstn
Ln also experi-
enced an alleviation of hyperinsulinemia. Thus, Mstn
deﬁciency led to a more dramatic effect on lean and fat
mass accumulation in males than it did in females, but
HOMA-IR levels in basal and challenged states were
normalized for both male and female HFD-fed Mstn
Ln/Ln
mice. To explore more directly whether Mstn is linked to
insulin sensitivity independent of its effects on body
composition, we tested Mstn
Ln/Ln mice that had been
chronically administered Mstn. Mature Mstn
Ln/Ln animals
treated with exogenous Mstn for up to 5 days show signs
of whole-body insulin resistance.
Circulating adiponectin levels decrease with diet-in-
duced obesity in Mstn
/Ln mice, consistent with numerous
studies showing an inverse relationship between obesity
and circulating adiponectin in mice, monkeys, and humans
(16). We further show that a near-complete loss of Mstn
function (Mstn
Ln/Ln) leads to a reduction in circulating
adiponectin in standard diet–fed animals that is not af-
fected by high-fat feeding. Consistent with our results,
Zhao et al. (17) showed that transgenic overexpression of
the inhibitory Mstn propeptide led to a decrease in circu-
lating adiponectin in mice fed a normal-fat diet, but they
also showed that circulating adiponectin went up in trans-
genic animals fed a high-fat diet compared with either
wild-type mice on an HFD or transgenic mice on a
normal-fat diet. In a subsequent report, Suzuki et al. (18)
showed that the increase in circulating adiponectin in
transgenic, high-fat–fed mice is due to increased expres-
sion in epididymal fat pads. In addition to upregulating
adiponectin expression, Mstn propeptide transgenic mice
also upregulated Ppara and Pparg expression in white
adipose tissue (18). Thus, it would appear that Mstn
activity inhibits adipogenesis. The literature, however, is
unclear on this point, with one group (5) reporting promo-
tion of adipogeneis by Mstn in the mesenchymal multipo-
tent stem cell line 10T1/2 and other groups (19,20)
reporting inhibition of adipocyte differentiation of 3T3-L1
cells. The effect of Mstn on fat deposition in adult mice is
also unclear, with one group (20) reporting a decrease and
another (21) reporting no effect. In Fstl3 knockout mice,
a decrease in visceral fat was attributed to increased
Mstn activity (22). The controversy about the role of
Mstn in adipogenesis and fat deposition notwithstand-
ing, Mstn
Ln/Ln mice represent a unique model in that the
insulin sensitivity despite high-fat feeding does not
seem to depend on adiponectin.
Noteworthy, the protection of whole-body insulin sensi-
tivity persists during a prolonged HFD and coincides with
improved liver insulin resistance and decreased hepatic
lipid accumulation and steatosis. There is also a differen-
tial effect on gene expression, as inﬂammatory genes were
FIG. 5. Whole-body, muscle, and liver insulin sensitivity of 11-month-old HFD-fed Mstn
Ln/Ln mice was improved as determined by the
hyperinsulinemic-euglycemic clamp method. A: Rate of glucose infusion needed to stabilize glycemia at 150 mg/dl over the ﬁnal 30 min of a 2-h
clamp (GINF). B: GDR. C: HGP. *P < 0.05 vs. HFD-fed Mstn
/Ln mice (n  7–11). Data are means  SE. , basal; f, insulin. D:
Serine-phosphorylated IRS-1 in liver of homozygous and heterozygous mutant mice. The graphed data are means  SE (n  4 per genotype). E:
Insulin-stimulated Akt phosphorylation in liver of homozygous and heterozygous mutant mice. , basal; u, insulin.
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Western blotting liver extracts revealed hepatic insulin
action to be markedly improved. Thus, we found insulin-
stimulated Akt-1 phosphorylation is enhanced, while IRS-1
serine phosphorylation is diminished. These ﬁndings are
consistent with improvements to hepatic insulin sensitiv-
ity in HFD-fed Mstn
Ln/Ln mice.
We found that homozygous Mstn mutation led to ro-
bustly decreased Cd36 gene expression in liver, decreased
Tnf, Il6, F4/80, and Gpr43 gene expression in fat and
Mstn Mstn
Mstn Mstn Mstn Mstn Mstn Mstn Mstn Mstn Mstn Mstn
Mstn Mstn Mstn Mstn Mstn Mstn Mstn Mstn
FIG. 6. Proinﬂammatory cytokine production in fat and muscle of HFD-fed male Mstn
Ln/Ln and Mstn
/Ln mice. The mRNA levels for Tnf, Il6, IL1,
F4/80, and Gpr43 genes in abdominal fat (A) or quadriceps muscle (B) of male mice maintained long term on an HFD were measured by
quantitative PCR (n  6 per genotype). Values were normalized to the amount of mRNA found in control (Mstn
/Ln) tissue. *Signiﬁcantly
different from Mstn
/Ln (P < 0.05).
FIG. 7. Hepatic Tnf, Il6, Il1, F4/80, and Gpr43 gene expression, lipid accumulation, and pathology. A: mRNA for cellular markers of
inﬂammation was measured by qPCR in liver samples from Mstn
Ln/Ln and Mstn
/Ln mice (n  6 per genotype). B: Hemotoxylin and eosin (a, c, e,
and g) or Oil Red O (b, d, f, and h) staining of liver sections dissected from Mstn
/Ln and Mstn
Ln/Ln animals. (A high-quality representation of this
ﬁgure is available in the online issue.)
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pared with the heterozygous Mstn
Ln mutation. F4/80 is
expressed in macrophages and serves as a surrogate for
macrophage inﬁltration of tissue. Gpr43 is also expressed
in macrophages, but, unlike F4/80, it is upregulated when
macrophages are stimulated with lipopolysaccharide in
vitro (data not shown). Thus, Gpr43 serves as a marker of
macrophage activation. While a reduction in Tnf, Il6,o r
Gpr43 in muscle alone could have improved insulin sen-
sitivity in lean Mstn
Ln/Ln mice, the tissue-selective reduc-
tions in proinﬂammatory genes may indicate that cross-
talk mediated through cytokines is turned down and
perhaps suggest reduced TNF production in muscle and
fat protects liver against obesity-induced insulin resis-
tance. Since obesity is associated with increases to resi-
dent macrophage cells in insulin-sensitive tissues, muscle
and fat could contribute to expanding pools of inﬂamma-
tory cytokines that may be elevated and thereby subse-
quently affect liver, once immune cell markers of
inﬂammation increase. Along with plasma TNF levels,
Tnf, F4/80, and Gpr43 expression all markedly decrease
by 50–75% in both muscle and fat of Mstn
Ln/Ln mice
compared with Mstn
/Ln mice. Further, we see that
chronic Mstn peptide treatment of naïve mice markedly
elevates TNF. The increases in lean animals receiving
Mstn compared with placebo suggest that TNF produc-
tion is directly inﬂuenced by Mstn treatments. While it is
possible that several mediators of insulin resistance may
be affected by Mstn, TNF is increased directly by Mstn
treatments that do not alter body or tissue weights,
supporting our hypothesized connection of Mstn to proin-
ﬂammatory cytokines. It also seems possible that by
increasing TNF production, hepatic insulin resistance
might develop along with ectopic fat storage, possibly
through select effects on FFA uptake in hepatocytes. Ruan
et al. (23) showed that continuous administration of TNF
for 1 day leads to insulin resistance and that there are
tissue-selective increases in CD36 gene expression in liver,
but not fat, of mature lean rats. Koonen et al. (24) found
that adenovirus-mediated overexpression of liver CD36
gene expression is sufﬁcient to induce lipid accumulation
in hepatocytes of standard diet–fed mice and suggested
that postnatal development of dyslipidemia associated
with DIO could be a consequence of liver CD36 upregula-
tion. Hence, Mstn production could lead to increases in
inﬂammatory signals, such as TNF, that promote lipid
storage in liver and induce insulin resistance.
Our results support the idea that obesity-induced insulin
resistance indirectly develops from adiposity and muscle
mass. A recently published study by Izumiya et al. (25)
reported that when mice are exhibiting a high lean/low–
body fat phenotype, due to constitutively active Akt-1
leading to modestly elevated amounts of muscle, in-
creased metabolic rates, and strikingly greater numbers of
C
A B
D
FIG. 8. GDF-8 treatment studies. A: Insulin resistance in HFD-fed Mstn-treated () or untreated (‚) female Mstn
Ln/Ln mice. Placebo-treated
HFD-fed Mstn
/Ln females are shown for comparison (). B: Plasma TNF levels in HFD-fed Mstn-treated () or untreated (p) Mstn
Ln/Ln female
mice. Placebo-treated HFD-fed Mstn
/Ln females are shown for comparison (f). *P < 0.05 vs. untreated. C: Body weight. D: Liver weights. All data
are shown as means  SE with n  5–6 per group.
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liver. Izumiya et al. speculate that type 2 muscle ﬁbers
release myokines that oppose detrimental actions of adi-
pocytokines on liver. Like animals of this study, Mstn gene
knockout mice are reported to have greater numbers of
type 2 muscle ﬁbers (26). Yet, Mstn-deﬁcient mice have
normal metabolic rates but are still protected against liver
insulin insensitivity. Also, because type 2 ﬁbers would be
expected to affect glucose uptake, Mstn-deﬁcient mice
could be affected by glucose utilization, too, due to mass
action, which attenuates hyperglycemia. Muscle glucose
uptake may be affecting to Mstn
Ln/Ln mice, since there are
differences in glucose tolerance between HFD-fed wild-
type mice and HFD-fed Mstn
/Ln mice (online appendix).
Interestingly, there are no overt differences in plasma
insulin levels, suggesting glucose tolerance has secondary
importance.
In conclusion, these results support an inﬂammatory
role for Mstn expression and show how this could occur.
Knowing that muscle is an abundant tissue, susceptible to
chronic inﬂammation and of great importance to whole-
body insulin sensitivity, even modest amounts of chronic
Mstn signaling may lead to inﬂammatory cytokine produc-
tion, insulin resistance, and liver steatosis. Therefore, we
conclude that severe Mstn deﬁciency decreases inﬂamma-
tion in muscle and this protects against obesity-induced
insulin resistance.
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